1 World Health Organization. WHO Coronavirus (COVID-19) Dashboard, <https://covid19.who.int> (2021).
2 Wells, C. R. et al. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proc Natl Acad Sci U S A117, 7504-7509, doi:10.1073/pnas.2002616117 (2020).
3 Osayomi, T. et al. A Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-Vaccine Hypothesis to the Test. Earth Systems and Environment, doi:10.1007/s41748-021-00234-5 (2021).
4 Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science368, 395-400, doi:10.1126/science.aba9757 (2020).
5 Costantino, V., Heslop, D. J. & MacIntyre, C. R. The effectiveness of full and partial travel bans against COVID-19 spread in Australia for travellers from China during and after the epidemic peak in China. Journal of travel medicine27, doi:10.1093/jtm/taaa081 (2020).
6 Gao, Y. et al. A cluster of the Corona Virus Disease 2019 caused by incubation period transmission in Wuxi, China. The Journal of infection80, 666-670, doi:10.1016/j.jinf.2020.03.042 (2020).
7 Tindale, L. C. et al. Evidence for transmission of COVID-19 prior to symptom onset. eLife9, doi:10.7554/eLife.57149 (2020).
8 Yu, P., Zhu, J., Zhang, Z. & Han, Y. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. J Infect Dis221, 1757-1761, doi:10.1093/infdis/jiaa077 (2020).
9 Johansson, M. A. et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA network open4, e2035057, doi:10.1001/jamanetworkopen.2020.35057 (2021).
10 Nie, X. et al. Epidemiological Characteristics and Incubation Period of 7015 Confirmed Cases With Coronavirus Disease 2019 Outside Hubei Province in China. J Infect Dis222, 26-33, doi:10.1093/infdis/jiaa211 (2020).
11 Qin, J. et al. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. Science advances6, eabc1202, doi:10.1126/sciadv.abc1202 (2020).
12 Lauer, S. A. et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal medicine172, 577-582, doi:10.7326/M20-0504 (2020).
13 Gussow, A. B., Auslander, N., Wolf, Y. I. & Koonin, E. V. Prediction of the incubation period for COVID-19 and future virus disease outbreaks. BMC Biol.18, 186, doi:10.1186/s12915-020-00919-9 (2020).
14 Lai, C. et al. Shorter incubation period is associated with severe disease progression in patients with COVID-19. Virulence11, 1443-1452, doi:10.1080/21505594.2020.1836894 (2020).
15 McAloon, C. et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open10, e039652, doi:10.1136/bmjopen-2020-039652 (2020).
16 Backer, J. A., Klinkenberg, D. & Wallinga, J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin25, doi:10.2807/1560-7917.ES.2020.25.5.2000062 (2020).
17 Li, Q. et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine382, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).
18 He, W., Yi, G. Y. & Zhu, Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. J Med Virol92, 2543-2550, doi:10.1002/jmv.26041 (2020).
19 Lu, Q. B. et al. Epidemiological parameters of COVID-19 and its implication for infectivity among patients in China, 1 January to 11 February 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin25, doi:10.2807/1560-7917.ES.2020.25.40.2000250 (2020).
20 Lai, C. K. C. et al. Epidemiological characteristics of the first 100 cases of coronavirus disease 2019 (COVID-19) in Hong Kong Special Administrative Region, China, a city with a stringent containment policy. International journal of epidemiology49, 1096-1105, doi:10.1093/ije/dyaa106 (2020).
21 Bi, Q. et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases20, 911-919, doi:10.1016/s1473-3099(20)30287-5 (2020).
22 Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol.19, 141-154, doi:10.1038/s41579-020-00459-7 (2021).
23 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
24 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China Cdc Weekly2, 113-122, doi:10.46234/ccdcw2020.032 (2020).
25 Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet395, 1054-1062, doi:10.1016/s0140-6736(20)30566-3 (2020).
26 Smits, S. L. et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog6, e1000756, doi:10.1371/journal.ppat.1000756 (2010).
27 Opal, S. M., Girard, T. D. & Ely, E. W. The immunopathogenesis of sepsis in elderly patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America41 Suppl 7, S504-512, doi:10.1086/432007 (2005).
28 Shakiba, M., Nazemipour, M., Heidarzadeh, A. & Mansournia, M. A. Prevalence of asymptomatic COVID-19 infection using a seroepidemiological survey. Epidemiology and infection148, e300, doi:10.1017/S0950268820002745 (2020).
29 Oran, D. P. & Topol, E. J. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Annals of internal medicine173, 362-367, doi:10.7326/M20-3012 (2020).
30 Quilty, B. J., Clifford, S., Flasche, S., Eggo, R. M. & group, C. n. w. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin25, doi:10.2807/1560-7917.ES.2020.25.5.2000080 (2020).
31 Testing Team, L. & Zhang, W. Local Outbreak of COVID-19 in Shunyi District Attributed to an Asymptomatic Carrier with a History of Stay in Indonesia — Beijing Municipality, China, December 23, 2020. China Cdc Weekly3, 214-217, doi:10.46234/ccdcw2020.062 (2021).
32 Jara, A. et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine, doi:10.1056/NEJMoa2107715 (2021).
33 Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England journal of medicine385, 585-594, doi:10.1056/NEJMoa2108891 (2021).
34 Team, C. C.-V. B. C. I. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR. Morbidity and mortality weekly report70, 792-793, doi:10.15585/mmwr.mm7021e3 (2021).
35 Philomina, J. B. et al. Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India. The Journal of infection83, 237-279, doi:10.1016/j.jinf.2021.05.018 (2021).
36 Hacisuleyman, E. et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. The New England journal of medicine384, 2212-2218, doi:10.1056/NEJMoa2105000 (2021).
37 Welch, B. L. On the Comparison of Several Mean Values - an Alternative Approach. Biometrika38, 330-336, doi:DOI 10.1093/biomet/38.3-4.330 (1951).